Kit Knightly This week has seen several timely reminders that the Covid narrative is not done. It may have lost its number 1 spot at the top of the “news” charts, but it’s not dead. It’s just resting. While the big red numbers at the top of every front page are now casualties instead of …
By Meryl Nass, MD | March 14, 2022 Pfizer’s Bourla says we need a 4th shot. Pfizer sold $36.8 billion dollars’ worth of COVID vaccines in 2021, making its vaccine the top-selling pharmaceutical product in history. Pfizer has estimated its COVID vaccine sales for 2022 at $32 billion. Albert Bourla says we need a 4th dose of […]
Peter Ford | Left and Right are united in baying for what amounts to self-abuse, especially as the poor will bear the brunt.
By John Droz, Jr., M.S. | The Defender | March 7, 2022 The U.S. Food and Drug Administration (FDA) in December 2021 granted Emergency Use Authorization (EUA) to two COVID-19 early treatment oral drugs: Pfizer’s Paxlovid and Merck’s molnupiravir. This was a major milestone, as until then, there were no FDA-endorsed pharmaceutical pill options for people diagnosed with COVID-19. The standard […]
Julien Charles The Frankfurt School predecessor and Marxist author Walter Benjamin was fascinated by the curious transformations of capitalism from the mid-to-late 1800s, when Marx wrote, to the early 20th century of Benjamin’s day. In the industrial era Marx observed, commodities were primarily viewed as raw materials and basic goods. Marx focused on production. By …
Children’s Health Defense | March 03, 2022 Washington, DC, — In a 55,000-page set of documents released on Tuesday, the U.S. Food and Drug Administration’s (FDA’s) Center for Biologics Evaluation and Research (CBER) is for the first time allowing the public to access data Pfizer submitted to FDA from its clinical trials in support of […]
… Including Those Caused by COVID Vaccines By Michael Nevradakis, Ph.D. | The Defender | February 24, 2022 Two major pharmaceutical companies chose February, the month of love — or hearts — to launch an advertising campaign urging people experiencing heart issues for the first time to visit their doctors. Pfizer and Bristol Myers Squibb (BMS) […]
Desert Review | Many top investors are not going with the conventional wisdom, but doing their own research instead.
Le chiffre d'affaires de Pfizer est en hausse de 95 % en 2021. Il doit cet incroyable résultat à ses ventes de vaccin anti-Covid. Ses bénéfices, eux, ont plus que doublé. En 2022, Pfizer espère vendre 32 milliards de dollars de vaccins et 22 milliards de dollars de médicaments anti-coronavirus… pour atteindre un chiffre d'affaires record de 100 milliards de dollars.
Le chiffre d'affaires de Pfizer est en hausse de 95 % en 2021. Il doit cet incroyable résultat à ses ventes de vaccin anti-Covid. Ses bénéfices, eux, ont plus que doublé. En 2022, Pfizer espère vendre 32 milliards de dollars de vaccins et 22 milliards de dollars de médicaments anti-coronavirus… pour atteindre un chiffre d'affaires record de 100 milliards de dollars.
